Edwards Q2 sales up 11.9% to $1.53B; raises full-year guidance

Edwards Lifesciences Corp

2025-Q2 EPS reported $1.18 revenue$2,944,900,000

Q2 GAAP EPS $0.57; adjusted EPS $0.67.
TAVR sales $1.1B (+8.9%); TMTT $134.5M (+61.9%); Surgical $267M (+7.7%).
Full-year sales growth guidance raised to 9-10% (from 8-10%); adjusted EPS expected at high end of $2.40-$2.50.
SAPIEN M3 CE Mark approved in Q2; 10-year PARTNER II data affirm durability.
Q3 guidance: sales $1.46-$1.54B, adjusted EPS $0.54-$0.60.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.